Double-check your math before every draw
Hypertension 60 , 757764 (2012)
New pharmacological treatments, including incretin therapies, have shown significant weight loss and cardiovascular benefits
1 Guidelines, manufacturers, and FDA warnings have erred on the side of caution and recommend careful use of GLP-1 RAs in patients with a history or high risk of pancreatitis
Resources We Trust Cleveland Clinic: This Is How to Lose Weight the Right Way and Keep It Off Johns Hopkins Medicine: Maintaining Weight Loss Massachusetts General Hospital: Fitness for People Taking GLP-1 Agonists: A Comprehensive Guide WashU Medicine: Stopping GLP-1 Drugs Can Quickly Erase Cardiovascular Benefits Yale School of Medicine: What Is the Impact of GLP-1s in Older Adults With Obesity
In the ELIXA [66], EXSCEL [68], and PIONEER 6 [67,71] studies, treatments of exenatide twice-daily, exenatide once-weekly, and oral semaglutide groups were non-inferior to placebo in terms of CV disease safety, respectively